Saturday 17 October 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 188.0%, free cash flow fell 78.3% and total debt fell 11.5%, each against the same quarter a year earlier.
32.10
2.16
−6.30%
Follow DFTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
6.95 | 4.69 | 6.29 | 3.30 |
+8 more quarters Free account |
Net Debt/EBITDA |
13.70 | 5.67 | 7.87 | 3.71 | |
Debt/Assets |
3.28% | 10.16% | 9.22% | 17.05% | |
Debt/Equity |
0.04 | 0.15 | 0.12 | 0.31 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.55 | 0.85 | 0.44 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(60.89) | (47.57) | (37.52) | (35.85) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.05 | 0.05 | 0.08 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.48) | (0.39) | (0.48) | (0.34) | |
Cash per Share |
9.79 | 3.43 | 4.61 | 2.43 | |
Shareholders Equity per Share |
8.30 | 2.56 | 3.72 | 1.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.30 | 2.56 | 3.72 | 1.52 | |
Free Cash Flow |
(52.78) | (42.63) | (42.97) | (29.57) | |
Working Capital |
934.90 | 299.45 | 352.62 | 150.43 | |
Net Current Asset Value |
897.88 | 258.12 | 311.55 | 109.53 | |
| Other line items | |||||
Quick Ratio |
6.89 | 4.60 | 6.17 | 3.20 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.48) | (0.39) | (0.48) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.59 | 4.70 | 3.68 | 5.13 | |
Average Assets |
689.00 | 338.31 | 371.13 | 278.34 | |
Average Common Equity |
552.04 | 250.83 | 286.89 | 196.39 |
Columns are period end dates